A detailed history of Jpmorgan Chase & CO transactions in Arca Biopharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16 shares of ABIO stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16
Previous 18 11.11%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.71 - $4.0 $3 - $8
-2 Reduced 11.11%
16 $0
Q1 2024

May 10, 2024

BUY
$1.58 - $1.78 $3 - $3
2 Added 12.5%
18 $0
Q4 2023

Feb 12, 2024

BUY
$1.7 - $2.05 $6 - $8
4 Added 33.33%
16 $0
Q3 2023

Nov 14, 2023

BUY
$2.01 - $2.07 $24 - $24
12 New
12 $0
Q2 2022

Aug 11, 2022

SELL
$2.2 - $2.53 $1,485 - $1,707
-675 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$1.77 - $2.49 $1,194 - $1,680
675 New
675 $2,000

Others Institutions Holding ABIO

About ARCA biopharma, Inc.


  • Ticker ABIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,410,100
  • Description
  • ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...
More about ABIO
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.